Suvoda launches Sofia, a new AI assistant to simplify management of clinical trials

March 05, 2025 03:17 PM GMT | By Cision
Follow us on Google News: https://kalkinemedia.com/resources/assets/public/images/google-news.webp

From many clicks to one query, drug supply managers can more quickly access, analyze, and visualize the trial supply data they need.

PHILADELPHIA, March 6, 2025 /PRNewswire/ -- Suvoda LLC, a global clinical trial technology company that specializes in complex studies in therapeutic areas like oncology, central nervous system (CNS), and rare disease, today announced the early adopter launch of Sofia, an artificial intelligence assistant designed to simplify how study teams access and review clinical trial information.

Sofia is available on the Suvoda Platform and can be enabled by sponsors looking to provide drug supply managers with efficient access to vital information through an intuitive chat interface, reducing what were once multi-screen, multi-click processes to simple conversations.

"When creating Sofia, we asked ourselves: What if clinical trial staff had an AI assistant that could alleviate their administrative burdens?" said E.K. Koh, Chief Product Officer at Suvoda. "Sofia became our answer. It's an exciting opportunity to streamline the management of clinical trials."

Built with Suvoda's commitment to reliability and security, Sofia brings greater efficiency to clinical trial operations, while adhering to data privacy and other regulatory requirements in clinical research.

Sofia's key capabilities include:

  • Streamlines Information Retrieval: Users access trial information through natural language queries that simplify navigation. They can now easily find answers that otherwise would span multiple screens, putting information they need at their fingertips.
  • Improves Productivity in Drug Supply Management: Drug supply managers can more quickly complete tasks like compare depot inventories, review drug lot releases for specific countries, check shipment details, and look over participant visit schedules, helping reduce workload and support operational efficiency.
  • Provides Reliable Responses: Sofia answers questions using expert instructions developed by subject matter experts with deep industry experience. It will "show its work" to users who wish to verify the results and will only answer questions that it has been trained on, helping avoid hallucinations in the answers that plague typical AI tools.
  • Includes Privacy Controls: Built specifically for clinical trials, Sofia operates with safeguards, including restrictions to study data based on user role which keeps customer data accessible to only authorized users and helps to maintain the study blind. Sofia also has guardrails to protect customer and patient data from exposure to public domain AI models.
  • Creates Visualizations: Sofia can create charts, graphs, and tables to help users more easily digest data.
  • Supports Global Operations: Individuals can converse with Sofia in their preferred language.

Sofia is currently optimized for drug supply managers using Suvoda Interactive Response Technology (IRT), with plans to expand to other users and products across the Suvoda Platform. This strategic rollout demonstrates Suvoda's dedication to thoughtful innovation that prioritizes reliability and user experience in clinical trial technology.

"There is a lot of hype around AI, but there is also a lot of promise," said Koh. "We've approached our work with Sofia with extreme diligence because in clinical trials there is no room for error."

Named after a Greek word for "wisdom," Sofia embodies Suvoda's guiding principle to enable clinical trial sponsors, sites, and patients to Trial Wisely. It is one more example of Suvoda's determination to smooth clinical trial complexity and give sponsors and sites the control over their trials to more efficiently bring life-saving therapies to those who need them most.

About Suvoda

Suvoda is a global clinical trial technology company specializing in complex, life-sustaining studies in therapeutic areas like oncology, central nervous system (CNS), and rare diseases. Founded in 2013 by experts in eClinical technologies, Suvoda empowers clinical trial professionals to manage the most urgent moments in the most urgent trials through advanced software solutions delivered on a single platform. Headquartered outside Philadelphia, Suvoda also maintains offices in Portland, OR, Barcelona, Spain, Bucharest and Iasi, Romania, and Tokyo, Japan. The company's Net Promoter Score (NPS) consistently exceeds the technology industry average, contributing to the company being selected by trial sponsors and CROs to support more than 1,800 trials across 95 countries. To learn more, visit suvoda.com. Follow Suvoda on LinkedIn.

For additional information please contact:

Robin Abadia, Director External Communications, Suvoda
[email protected]

Logo - https://mma.prnasia.com/media2/1759317/Suvoda_Logo.jpg?p=medium600 


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Limited, Company No. 12643132 (“Kalkine Media, we or us”) and is available for personal and non-commercial use only. Kalkine Media is an appointed representative of Kalkine Limited, who is authorized and regulated by the FCA (FRN: 579414). The non-personalized advice given by Kalkine Media through its Content does not in any way endorse or recommend individuals, investment products or services suitable for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a qualified financial planner and/or adviser. No liability is accepted by Kalkine Media or Kalkine Limited and/or any of its employees/officers, for any investment loss, or any other loss or detriment experienced by you for any investment decision, whether consequent to, or in any way related to this Content, the provision of which is a regulated activity. Kalkine Media does not intend to exclude any liability which is not permitted to be excluded under applicable law or regulation. Some of the Content on this website may be sponsored/non-sponsored, as applicable. However, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content. Some of the images/music/video that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music or video used in the Content unless stated otherwise. The images/music/video that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.

AI on the Rise: A Look at Top AI Companies and Their Stocks

Recent Articles

Investing Tips

Previous Next